1082745-50-3

Basic information

• Product Name: 5-aMino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxaMide
• Synonyms: 5-aMino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxaMide;5-AMino-1-(tetrahydro-pyran-4-yl)-1H-pyrazole-4-carboxylic acid aMide;5-Amino-1-(oxan-4-yl)-1H-pyrazole-4-carboxamide;5-Amino-1-(tetrahydro-2H-pyran-4-yl);EOS-62038
• CAS NO: 1082745-50-3
• Molecular Formula: C₉H₁₄N₄O₂
• Molecular Weight: 210.23306
• Mol File: 1082745-50-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 453.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.57±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 15.14±0.50(Predicted)
• CAS DataBase Reference: 5-aMino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-aMino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxaMide(1082745-50-3)
• EPA Substance Registry System: 5-aMino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxaMide(1082745-50-3)

Safety Data

• Hazardous Substances Data: 1082745-50-3(Hazardous Substances Data)

Usage

General Description

5-Amino-1-(tetrahydro-2h-pyran-4-yl)-1h-pyrazole-4-carboxamide is a chemical compound with the formula C10H15N3O2. It falls under the classification of organic compounds, specifically as an amino pyrazole, with applications in various chemical reactions due to its structural properties. Its systematic name is 4-(5-Amino-1H-pyrazol-1-yl)-1,2-dihydro-2-oxo-pyran-1-carboxamide, indicating the presence of a pyrazole ring, a pyran ring, an amino group and a carboxamide group in its structure. As with all chemicals, proper care should be taken while handling it, as its specific health effects are generally not known or studied.

Upstream product

• 1082745-49-0 5-amino-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carbonitrile 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 693287-79-5 N’-(tetrahydropyran-4-yl)hydrazinecarboxylic acid tert-butyl ester 
• 693287-78-4 N’-(tetrahydropyran-4-ylidene)hydrazinecarboxylic acid tert-butyl ester 
• 116312-69-7 tetrahydro-2H-pyran-4-yl-hydrazine 

Downstream Products

• 1189767-09-6 6-benzyl-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-06-6 6-((3S,4S)-1-benzyl-4-ethylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-07-7 6-((3S,4S)-1-(2-fluorobenzyl)-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082743-98-3 6-((3S,4S)-1-(3-fluorobenzyl)-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-05-5 6-((3S,4S)-1-(4-fluorobenzyl)-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-10-2 6-((3S,4S)-1-(4-methoxybenzyl)-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082744-20-4 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1082743-70-1 6-((3S,4S)-1-benzyl-4-methylpyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 1236858-52-8 PF-04449613 
• 1236858-84-6 4-[(1-{1-[4-oxo-1-(tetrahydro-2H-pyran-4-yl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl]ethyl}azetidin-3-yl)oxy]benzonitrile 
• 1548588-87-9 6-[(2-chlorophenoxy)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
• 1548588-46-0 6-(phenoxymethyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease

A series of dual-target AChE/PDE9A inhibitor compounds were designed, synthesized, and evaluated as anti-Alzheimer's Disease (AD) agents. Among these target compounds, 11a (AChE: IC50 = 0.048 μM; PDE9A: IC50 = 0.530 μM) and 11b (AChE: IC50 = 0.223 μM; PDE9A: IC50 = 0.285 μM) exhibited excellent and balanced dual-target AChE/PDE9A inhibitory activities. Meanwhile, those two compounds possess good blood-brain barrier (BBB) penetrability and low neurotoxicity. Especially, 11a and 11b could ameliorate learning deficits induced by scopolamine (Scop). Moreover, 11a could also improve cognitive and spatial memory in Aβ25-35-induced cognitive deficit mice in the Morris water-maze test. In summary, our research developed a series of potential dual-target AChE/PDE9A inhibitors, and the data indicated that 11a was a promising candidate drug for the treatment of AD.

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

Design and discovery of 6-[(3 s,4 s)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-1-(tetrahydro-2 h -pyran-4-yl)-1,5-dihydro-4 h -pyrazolo[3,4- d ]pyrimidin-4-one (PF-04447943), a selective brain penetrant pde9a inhibitor for the treatment of cognitive disorders

6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl] -1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943) is a novel PDE9A inhibitor identified using parallel synthetic chemistry and structure-based drug design (SBDD) and has advanced into clinical trials. Selectivity for PDE9A over other PDE family members was achieved by targeting key residue differences between the PDE9A and PDE1C catalytic site. The physicochemical properties of the series were optimized to provide excellent in vitro and in vivo pharmacokinetics properties in multiple species including humans. It has been reported to elevate central cGMP levels in the brain and CSF of rodents. In addition, it exhibits procognitive activity in several rodent models and synaptic stabilization in an amyloid precursor protein (APP) transgenic mouse model. Recent disclosures from clinical trials confirm that it is well tolerated in humans and elevates cGMP in cerebral spinal fluid of healthy volunteers, confirming that it is a quality pharmacological tool for testing clinical hypotheses in disease states associated with impairment of cGMP signaling or cognition.